Module 1: The Last Mile — Why Evidence Alone Does Not Secure Market Access

Life science companies invest heavily in generating clinical and economic evidence, yet market access outcomes frequently disappoint — not because the evidence is weak but because it is poorly communicated. This module introduces the concept of value communication as a distinct discipline and examines what separates effective payer engagement from technical data presentation.

• why evidence generation and evidence communication are different competencies — and why most organisations underinvest in the latter
• the common failure modes in value communication — technical overload, misaligned endpoints, generic messaging and failure to address the audience’s actual decision criteria
• how payer and procurement decision-making works in practice — the interplay between clinical evaluation, economic assessment and budget considerations
• how AI-powered tools are beginning to reshape value communication workflows — from drafting initial value messages to analysing payer feedback at scale

Module 2: Know Your Audience — Mapping Payer and Procurement Decision-Makers

A value message that resonates with a health technology appraisal committee will not necessarily land with a hospital procurement panel, a German sickness fund or a US pharmacy and therapeutics committee. This module teaches participants to map the decision landscape systematically, identifying the relevant audiences, their decision criteria and the evidence formats they expect to receive.

• the key payer and procurement archetypes — HTA bodies, hospital formulary committees, procurement hubs, regional purchasing organisations and integrated care systems
• how decision criteria differ across audiences — clinical effectiveness, budget impact, unmet need, patient-reported outcomes and operational considerations
• the concept of the “value filter” — understanding what each audience screens for first and how to structure messages accordingly
• conducting payer research through advisory boards, published frameworks and engagement programmes to validate assumptions before developing materials

Module 3: Building the Value Story — From Evidence to Message

The transition from a body of evidence to a coherent value story is where most organisations struggle. This module covers the structured process of distilling clinical, economic and humanistic evidence into a value proposition and a set of key messages that can be adapted for different audiences and communication formats.

• the anatomy of a value proposition — defining the unmet need, the clinical differentiation, the economic argument and the patient or system benefit in a single coherent narrative
• translating incremental cost-effectiveness ratios, budget impact results and number needed to treat into language that non-technical decision-makers can understand and act on
• building a message hierarchy — primary, secondary and supporting messages — and mapping each message to its evidence base
• stress-testing value messages through objection mapping — anticipating the challenges that payers, clinicians and budget holders will raise and preparing evidence-based responses

Module 4: Value Dossiers and Payer Communication Materials

Value dossiers are the primary vehicle for communicating a product’s clinical, economic and humanistic value to payers and HTA bodies. This module examines the major dossier formats, their structural requirements and the principles that distinguish a compelling dossier from a mere data dump.

• the global value dossier — purpose, structure and how it serves as the master document from which all other payer materials are derived
• the AMCP dossier format — its specific structural requirements, evidence standards and how it differs from a global value dossier
• jurisdiction-specific dossier requirements — how submission formats vary across major HTA agencies and what this means for dossier planning
• quality standards and common pitfalls — how to critically appraise value communication materials for completeness, accuracy, internal consistency and alignment with the underlying evidence base

Module 5: Presenting Value — Slide Decks, Procurement Submissions and Live Presentations

Written dossiers are only part of the value communication landscape. Increasingly, market access outcomes depend on live presentations to procurement committees, formulary panels and HTA advisory groups — settings where the ability to present evidence clearly, handle questions confidently and adapt messaging in real time is critical.

• designing payer slide decks that lead with the decision-maker’s question rather than the manufacturer’s data — structure, visual design and narrative flow
• procurement presentations — how procurement frameworks and evaluation processes work and what evaluators look for
• handling objections and questions in live settings — frameworks for responding to challenges on comparator selection, evidence gaps, generalisability and budget impact assumptions
• using AI tools to prepare for payer meetings — simulating likely objections, generating tailored responses and rapidly retrieving supporting evidence during preparation

Module 6: Measuring, Refining and Sustaining Value Communication

Value communication is not a one-off deliverable — it is an ongoing process of testing, learning and refining. This module covers how to evaluate whether value messages are landing, how to use payer feedback to improve materials and how to build organisational capability in value communication over time.

• establishing feedback loops — using payer advisory boards, market access tracking and post-submission debriefs to assess whether value messages are resonating
• iterative refinement of value materials — how to update dossiers, slide decks and objection-handling frameworks as new evidence emerges or payer requirements evolve
• building internal value communication capability — the roles, processes and governance structures that sustain effective payer engagement across the product lifecycle
• the evolving landscape — how the increasing formalisation of HTA across life science sectors, the growth of outcomes-based contracting and the emergence of AI-assisted payer engagement are reshaping what effective value communication looks like